The feline leukemia virus (FeLV) disease model was used to conduct a toxicity and antiretrovirus efficacy trial of dextran sulfate (DS; molecular mass, 7,000 to 8,000 Da). In (12, 14) , infection (12, 13), syncytium formation (2, 12, 20) , and reverse transcriptase (3, 12, 13). DS has been used for more than 20 years as an anticoagulant and antilipemic agent in humans.
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The objective of the present investigation was to conduct a preliminary evaluation of DS for toxicity and antiretroviral prophylactic efficacy in the feline leukemia virus (FeLV) cat model. DS was administered by continuous intravenous infusion to assure adequate plasma concentrations. Previous studies with AIDS and AIDS-related complex patients given oral DS (1) were difficult to interpret because of low oral bioavailability of the compound (10) . Using the animal model also permitted examination of postmortem tissues to determine possible organ toxicity.
The in vitro antiviral activity of DS was evaluated against FeLV-infected feline lymphoid cells (3201 cell line). 3201 cells were incubated for 48 h in medium (41% RPMI 1640, 41% Lebovitz-15, 15% heat-inactivated fetal bovine serum, 2% L-glutamine, 1% penicillin-streptomycin) containing DS at concentrations of 0, 0.1, 0.5, 5, 10, 50, 100, 500, and 1,000 ,ug/ml. DS (Fig. 1 ). By comparison, 3'-azido-3'-deoxythymidine (AZT) inhibited FeLV antigen expression >80% at a concentration of 1.5 ,ig/ml in the same assay ( Fig. 1, inset) .
The in vivo prophylactic studies were designed to evaluate toxicity and prophylactic antiviral activity of DS in a small number of animals and to increase the number of animals at the dosage found to be subtoxic. DS was administered by continuous intravenous (i.v.) infusion by using the technique of Swenson et al. (18) . DS was dissolved in pyrogen-free saline, adjusted to pH 7.4 with 1 M NaOH, and passed through a 0.44-,um (pore size) filter A total of 11 cats were treated prophylactically with DS. One cat received 600 mg/kg/day; one cat received 240 mg/kg/day, which was subsequently reduced to 120 mg/kg/ day; five cats received 24 mg/kg/day; and four cats received 4.8 mg/kg/day. The effects of DS administration are shown in Table 1 . Dosages of 600 and 240 (120) mg/kg/day were excessively toxic, causing deaths of both cats. The 24-mg/ kg/day dosage was also toxic, causing deterioration of all five cats, which lead to euthanasia at 18 to 26 days after DS treatment began. The major organs targeted in these animals were the small and large intestines, which contained severe mucosal epithelial degeneration and necrosis with collapse of the lamina propria. Clinical signs of toxicity included lethargy, anorexia, anemia, and a slight left shift. One cat given 24 mg/kg/day also developed diarrhea after 15 days of therapy. The mean DS plasma concentration in the cats given 24 mg/kg/day was 47.7 jig/ml (range, 10.3 to 82.6), based on coagulation times (10) .
Four additional cats serving as uninfected controls received 24 mg/kg/day by continuous i.v. infusion as described above. All four cats developed clinical signs similar to those of the virus challenge animals and were euthanized after 19 (16) , was discounted because DS-treated uninfected controls displayed similar lesions.
We and others have used the FeLV cat model to evaluate the prophylactic activities of a variety of antiviral agents, including AZT (11, 19) , 2',3'-dideoxycytidine (15), phosphonoformate (18a), and 9-(2-phosphonylmethoxyethyl)adenine (11 
